At Fresenius, we are at the heart of healthcare. For all our activities, our patients take center stage. We focus on world-class therapies, which we continuously improve to keep pace with the major trends in healthcare. Our therapy focus is reflected in three platforms:
(Bio)Pharma
Biosimilars
IV Generics and Fluids
Clinical Nutrition
MedTech
Infusion and Nutrition Systems
Transfusion Medicine and Cell Therapies
Care Provision
Inpatient and Outpatient Treatments
Occupational Healthcare and Prevention
Reproductive Medicine
Furthermore, our Investment Company Fresenius Vamed expands our offering to:
Project Business and Services
Rehabilitation, Care and Health Tourism
An open dialog with our shareholders and the financial community is important to us. The Fresenius Investor Relations team will be happy to answer all your questions and inquiries.
You can submit your Feedback quickly and easily (anonymously if you prefer). You will be redirected to QuantiFire which conducts this survey in own controllership.
Fresenius SE & Co. KGaA
Investor Relations
Else-Kröner-Str. 1
D-61352 Bad Homburg
Germany
ir-fre@fresenius.com
Postal address:
Fresenius SE & Co. KGaA
Investor Relations
D-61346 Bad Homburg v.d.H.

Nick Stone
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com

Karen Janek
Assistant Investor Relations
T: +49 (0) 6172 608-2487
karen.janek@fresenius.com

Silke Zimmermann
Assistant Investor Relations
T: +49 (0) 6172 608-2464
silke.zimmermann@fresenius.com

Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com

Stefanie Drees
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com

Felix Klein
Director Investor Relations
T: +49 (0) 6172 608-96484
felix.klein@fresenius.com

Michael Otto
Director Investor Relations
T: +49 (0) 6172 608-2419
michael.otto@fresenius.com

Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com

Kacper Boborykin
Senior Manager Investor Relations
(US based)
T: +1 224 566 1998
kacper.boborykin@fresenius.com

Mara Sinsel
Senior Manager Investor Relations
T: +49 (0) 6172 608-96538
mara.sinsel@fresenius.com

Luca Thorißen
Senior Manager Investor Relations
T +49 6172 608-97049
luca.thorissen@fresenius.com

Annette Hainz
Manager Investor Relations
T: +49 (0) 6172 608-2604
annette.hainz@fresenius.com

Elisabeth Jung
Manager Investor Relations
T: +49 (0) 6172 608-2421
elisabeth.jung@fresenius.com
Bonds
Issuer | Volume in million | Coupon | Maturity |
---|---|---|---|
€750 | 1.875% | 2025 | |
€500 | 0.375% | 2026 | |
€500 | 4.25% | 2026 | |
€750 | 1.625% | 2027 | |
€750 | 0.75% | 2028 | |
CHF275 | 2.96% | 2028 | |
€500 | 2.875% | 2029 | |
CHF225 | 1.5975% | 2029 | |
€500 | 5.00% | 2029 | |
€550 | 2.875% | 2030 | |
€500 | 5.125% | 2030 | |
€500 | 5.125% | 2030 | |
€500 | 0.00% | 2025 | |
€700 | 2.125% | 2027 | |
€500 | 0.50% | 2028 | |
€500 | 0.875% | 2031 | |
€500 | 3.00% | 2032 |
New information
- Fresenius 2024 Notes - Notice of Optional Redemption Price (PDF, 141 KB)
- Fresenius 2024 Notes - Early Redemption Notice (PDF, 55 KB)
- Fresenius 2023 Notes - Early Redemption Notice (PDF, 68 KB)
- Entry into supplemental indenture €450 million 4.000% Senior Notes due 2024 (PDF, 108 KB)
- Consent Solicitation €450 million 4.000% Senior Notes due 2024 (PDF, 105 KB)
- Notice of release of subsidiary guarantees (PDF, 20 KB)